Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Drug

Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC

Fineline Cube Dec 22, 2022

China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor...

Company Drug

Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China

Fineline Cube Dec 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...

Policy / Regulatory

Shanghai Outlines Plans to Boost Healthcare and Pharma Industry

Fineline Cube Dec 22, 2022

Liu Wei, director of the market orders and trade division of the Shanghai Commerce Commission,...

Company Drug

Yantai Dongcheng Receives NMPA Approval for F18 PET Imaging Study

Fineline Cube Dec 22, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

Biomica Raises Funds for Tumor Immunity and IBD Drug Development

Fineline Cube Dec 22, 2022

Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round,...

Company Deals

Redpine Medical Raises ‘Hundreds of Millions’ in Series C Financing Round

Fineline Cube Dec 22, 2022

Redpine Medical, a single-use endoscope maker based in Guangzhou, has reportedly raised “hundreds of millions”...

Company Drug

Yipinhong’s AR882 Receives NMPA Approval for Gout Clinical Trial

Fineline Cube Dec 22, 2022

China-based Yipinhong Pharmacy Co., Ltd (SHA: 300723) has announced that its pipeline candidate AR882, under...

Company Drug

Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor

Fineline Cube Dec 22, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1,...

Company Deals

Sibionics Raises RMB 500 Million in Series D Financing Round

Fineline Cube Dec 21, 2022

Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD...

Company Deals

Waker Bioscience Raises Angel Funding for ISA Technology Upgrades

Fineline Cube Dec 21, 2022

Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens...

Drug

InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination

Fineline Cube Dec 21, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...

Company Deals

Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development

Fineline Cube Dec 21, 2022

Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens...

Company Deals Digital

PingAn Good Doctor Partners to Establish Lifestyle Medicine

Fineline Cube Dec 21, 2022

China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...

Company Deals

JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development

Fineline Cube Dec 21, 2022

China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...

Company Deals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

Fineline Cube Dec 21, 2022

China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...

Company Drug

Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data

Fineline Cube Dec 21, 2022

Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...

Company Drug

Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study

Fineline Cube Dec 21, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA)...

Company Deals

TowardPi Raises RMB 300 Million in Series C Financing Round

Fineline Cube Dec 20, 2022

China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB...

Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Posts pagination

1 … 552 553 554 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.